Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation… Read more
Paion AG (PAIOF) - Net Assets
Latest net assets as of June 2023: $-3.07 Million USD
Based on the latest financial reports, Paion AG (PAIOF) has net assets worth $-3.07 Million USD as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.24 Million) and total liabilities ($35.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.07 Million |
| % of Total Assets | -9.51% |
| Annual Growth Rate | -0.71% |
| 5-Year Change | -68.23% |
| 10-Year Change | -50.37% |
| Growth Volatility | 115.28 |
Paion AG - Net Assets Trend (2003–2022)
This chart illustrates how Paion AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Paion AG (2003–2022)
The table below shows the annual net assets of Paion AG from 2003 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $6.62 Million | -5.49% |
| 2021-12-31 | $7.00 Million | -67.12% |
| 2020-12-31 | $21.29 Million | +44.51% |
| 2019-12-31 | $14.73 Million | -29.25% |
| 2018-12-31 | $20.82 Million | -17.47% |
| 2017-12-31 | $25.23 Million | +1.15% |
| 2016-12-31 | $24.94 Million | -29.86% |
| 2015-12-31 | $35.56 Million | -43.20% |
| 2014-12-31 | $62.61 Million | +369.70% |
| 2013-12-31 | $13.33 Million | -14.40% |
| 2012-12-31 | $15.57 Million | +3458.48% |
| 2011-12-31 | $-463.67K | -103.87% |
| 2010-12-31 | $11.97 Million | -38.00% |
| 2009-12-31 | $19.30 Million | -38.77% |
| 2008-12-31 | $31.53 Million | -26.76% |
| 2007-12-31 | $43.05 Million | -18.39% |
| 2005-12-31 | $52.75 Million | +244.50% |
| 2004-12-31 | $15.31 Million | +102.02% |
| 2003-12-31 | $7.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Paion AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19734860678.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $71.34 Million | 1078.41% |
| Other Comprehensive Income | $-1.05 Million | -15.84% |
| Other Components | $144.54 Million | 2185.02% |
| Total Equity | $6.62 Million | 100.00% |
Paion AG Competitors by Market Cap
The table below lists competitors of Paion AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DT REAL ESTATE
MU:DRE2
|
$129.92K |
|
Nuveen Churchill Direct Lending Corp.
NYSE:NCDL
|
$129.92K |
|
KANSAI EL POWER
BE:KPO
|
$129.92K |
|
Sparindex INDEX EmMarkBoLokval
CO:SPVIEMMBLV
|
$130.02K |
|
RHOEN-KLINIKUM - Dusseldorf Stock Exchang
DU:RHK
|
$129.70K |
|
CGRE AG
F:CGX
|
$129.60K |
|
SHENANDOAH TELE (SH9.SG)
STU:SH9
|
$129.59K |
|
Insimbi Refractory Alloy Supply
JSE:ISB
|
$129.57K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paion AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 6,999,086 to 6,615,000, a change of -384,086 (-5.5%).
- Net loss of 579,000 reduced equity.
- Other comprehensive income increased equity by 69,673.
- Other factors increased equity by 125,241.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-579.00K | -8.75% |
| Other Comprehensive Income | $69.67K | +1.05% |
| Other Changes | $125.24K | +1.89% |
| Total Change | $- | -5.49% |
Book Value vs Market Value Analysis
This analysis compares Paion AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $6.44 | $0.02 | x |
| 2004-12-31 | $13.02 | $0.02 | x |
| 2005-12-31 | $28.22 | $0.02 | x |
| 2006-12-31 | $21.96 | $0.02 | x |
| 2007-12-31 | $17.22 | $0.02 | x |
| 2008-12-31 | $12.23 | $0.02 | x |
| 2009-12-31 | $6.34 | $0.02 | x |
| 2010-12-31 | $3.89 | $0.02 | x |
| 2011-12-31 | $-0.15 | $0.02 | x |
| 2012-12-31 | $4.96 | $0.02 | x |
| 2013-12-31 | $4.25 | $0.02 | x |
| 2014-12-31 | $15.12 | $0.02 | x |
| 2015-12-31 | $6.81 | $0.02 | x |
| 2016-12-31 | $4.58 | $0.02 | x |
| 2017-12-31 | $4.16 | $0.02 | x |
| 2018-12-31 | $3.26 | $0.02 | x |
| 2019-12-31 | $2.26 | $0.02 | x |
| 2020-12-31 | $3.16 | $0.02 | x |
| 2021-12-31 | $1.00 | $0.02 | x |
| 2022-12-31 | $0.93 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paion AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.74%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 5.77x
- Recent ROE (-8.75%) is above the historical average (-47.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -143.34% | -1532.97% | 0.07x | 1.32x | $-11.62 Million |
| 2004 | 1.15% | 1.04% | 0.66x | 1.68x | $-1.36 Million |
| 2005 | -9.02% | -25.30% | 0.28x | 1.25x | $-10.03 Million |
| 2007 | -29.47% | 0.00% | 0.00x | 1.28x | $-14.08 Million |
| 2008 | -39.90% | -397.32% | 0.06x | 1.56x | $-15.73 Million |
| 2009 | -67.53% | -850.30% | 0.04x | 1.84x | $-14.97 Million |
| 2010 | -77.32% | -206.82% | 0.17x | 2.24x | $-10.45 Million |
| 2011 | 0.00% | -421.16% | 0.26x | 0.00x | $-13.64 Million |
| 2012 | 102.80% | 59.71% | 0.95x | 1.82x | $14.45 Million |
| 2013 | -16.59% | -52.32% | 0.23x | 1.35x | $-3.54 Million |
| 2014 | -14.54% | -263.46% | 0.05x | 1.06x | $-15.37 Million |
| 2015 | -79.33% | -39395.04% | 0.00x | 1.22x | $-31.77 Million |
| 2016 | -80.65% | -472.05% | 0.11x | 1.52x | $-22.61 Million |
| 2017 | -47.93% | -208.11% | 0.18x | 1.26x | $-14.62 Million |
| 2018 | -47.74% | -359.36% | 0.11x | 1.17x | $-12.02 Million |
| 2019 | -47.62% | -87.70% | 0.32x | 1.69x | $-8.49 Million |
| 2020 | 10.44% | 11.31% | 0.70x | 1.32x | $93.16K |
| 2021 | -311.26% | -305.62% | 0.19x | 5.26x | $-22.49 Million |
| 2022 | -8.75% | -1.74% | 0.87x | 5.77x | $-1.24 Million |
Industry Comparison
This section compares Paion AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paion AG (PAIOF) | $-3.07 Million | -143.34% | N/A | $129.70K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |